



Clover Biopharmaceuticals, Ltd.

三葉草生物製藥有限公司*

(Incorporated in the Cayman Islands with limited liability)

(於開曼群島註冊成立的有限公司)

(Stock Code: 2197)

(股份代號: 2197)

NOTIFICATION LETTER

May 21, 2025

Dear Registered Shareholders^(Note 1),

Clover Biopharmaceuticals, Ltd. (the “Company”)

–Reminder letter regarding the Arrangement of Electronic Dissemination of Corporate Communications

Arrangement of Electronic Dissemination of Corporate Communications

References are made to the announcements of the Company dated March 27, 2024, June 20, 2024 and September 19, 2024 titled “Arrangement of Electronic Dissemination of Corporate Communications”, the Company is writing to remind you that the Company has adopted electronic dissemination of corporate communications (“**Corporate Communications**”), which means any documents issued or to be issued by the Company for the information or action of holders of any of its securities, including but not limited to (a) the directors’ report, its annual accounts together with a copy of the auditors’ report and, where applicable, its summary financial report; (b) the interim report and, where applicable, its summary interim report; (c) a notice of meeting; (d) a listing document; (e) a circular; (f) a reply slip; and (g) a proxy form.

Please note that both the English and Chinese versions of all future Corporate Communications will be available electronically on the website of the Company at www.cloverbiopharma.com and the website of The Stock Exchange of Hong Kong Limited (the “**Stock Exchange**”) at www.hkexnews.hk in place of printed copies.

Solicitation of electronic contact details

The Company has not received your email address for the electronic dissemination of Corporate Communications. To ensure timely receipt of the Actionable Corporate Communications^(Note 2), the Company recommends you to provide your email address by scanning your personalized QR code printed on the reply form on the reverse side (the “**Reply Form**”). Alternatively, you may sign and return the Reply Form to the Company’s Hong Kong share registrar (the “**Share Registrar**”), Computershare Hong Kong Investor Services Limited, at 17M Floor, Hopewell Centre, 183 Queen’s Road East, Wan Chai, Hong Kong, or return the Reply Form by sending an email to clover.ecom@computershare.com.hk.

If no valid and functional email address is provided by you, the Company will send to you by post at your address as appearing in the Company’s register of members maintained by the Share Registrar all future Actionable Corporate Communications in printed form, until such time when you have provided a valid and a functional email address to the Share Registrar for receiving the same. It is the responsibility of the shareholders to provide email address that is functional, and the Company will be considered to have complied with the Rules Governing the Listing of Securities on the Stock Exchange if it sends Actionable Corporate Communications to the email address provided by a shareholder without receiving any “non-delivery message”.

Request for Corporate Communications in printed form

If you want to receive future Corporate Communications in printed form, please complete and sign on the Reply Form enclosed and return it by post using the mailing label at the bottom of the Reply Form (a stamp is not needed if posted in Hong Kong) or by hand delivery to the Share Registrar, Computershare Hong Kong Investor Services Limited at 17M Floor, Hopewell Centre, 183 Queen’s Road East, Wanchai, Hong Kong. You may also send your request (specifying your name, address and request) via email to clover.ecom@computershare.com.hk or write to the Share Registrar. Please note that (i) selected instruction made previously to receive printed copies of Corporate Communications will be valid for one year from the receipt date of the shareholder’s instruction; (ii) if a shareholder did not make election previously and fails to indicate this time to receive printed copies of Corporate Communications, only electronic future Corporate Communications will be available; and (iii) the election to receive a printed version of all future Corporate Communications will be valid for one year from the receipt date of the shareholder’s instruction unless being revoked or superseded (whichever is earlier). Therefore, further request in writing will be required if a shareholder prefers to continue receiving printed copy of future Corporate Communications.

Should you have any queries relating to this letter, please call the service hotline of the Share Registrar at (852) 2862 8688 during business hours (9:00 a.m. to 6:00 p.m. (Hong Kong time), Monday to Friday, excluding Hong Kong public holidays).

Yours faithfully,
By order of the Board
Clover Biopharmaceuticals, Ltd.
Dr. Peng LIANG
Chairman of the Board

Note 1: This letter is addressed to registered shareholders of the Company who have not yet provided an email address for the timely receipt of actionable corporate communications. If you are a new registered shareholder, please read the arrangement for the electronic dissemination of corporate communications and provide your email address as recommended

Note 2: Actionable Corporate Communications refer to any corporate communications that seek instructions from issuer’s securities holders on how they wish to exercise their rights or make an election as the issuer’s securities holder.

*For identification purpose only



Clover Biopharmaceuticals, Ltd.

三葉草生物製藥有限公司*

(Incorporated in the Cayman Islands with limited liability)

(於開曼群島註冊成立的有限公司)

(Stock Code: 2197)

(股份代號: 2197)

通知信函

各位登記股東^(附註 1)：

三葉草生物製藥有限公司* (「本公司」)

以電子方式發佈公司通訊安排的提示信函

茲提述本公司日期為 2024 年 3 月 27 日、2024 年 6 月 20 日及 2024 年 9 月 19 日的公告，本公司謹此提醒閣下，公司已採用以電子方式發佈公司通訊(「公司通訊」)之安排，該公司通訊是指公司為向其任何證券持有人提供資訊或提醒其採取行動而發佈或將要發佈的任何文件，包括但不限於(a)董事報告、年度帳目以及審計報告副本以及(如適用)財務摘要報告；(b)中期報告及(如適用)其中期報告摘要；(c)會議通知；(d)上市文件；(e)通函；(f)回執；和(g)委任表格。

請注意，所有未來公司通訊的英文版和中文版將在公司網站 www.cloverbiopharma.com 和香港交易及結算所有限公司(「聯交所」)網站 www.hkexnews.hk 提供，以代替印刷本。

徵集電子聯絡資料

公司尚未收到閣下就接收公司通訊提供電子郵件地址。為確保及時收到可供採取行動的公司通訊^(附註 2)，公司建議閣下透過掃描本函背頁之回執(「回執」)上列印的閣下專屬二維碼來提供閣下的電子郵件地址。或者，閣下也可以填妥回執(「回執」)，並在上簽名，然後把回執交回公司的香港股份過戶登記處(「股份過戶處」)香港中央證券登記有限公司，地址為香港灣仔皇后大道東 183 號合和中心 17M 樓，或發送電子郵件至 clover.ecom@computershare.com.hk。

若閣下在回執中沒有提供有效且可用的電郵地址，本公司將根據股份過戶處所存置的股東名冊上所示的地址透過郵寄方式向閣下發送所有日後可供採取行動的公司通訊的印刷本，直至閣下向股份過戶登記處提供有效且可用的電郵地址以接收該等公司通訊。股東有責任提供有效的電子郵件地址，如果本公司向股東提供的電子郵件地址發送可供採取行動的公司通訊而未收到“未送達信息”，本公司將被視為已遵守聯交所證券上市規則。

要求收取公司通訊印刷本

如閣下欲收取日後公司通訊的印刷本，請填妥隨附的回執，並使用隨附之郵寄標籤(如在香港投寄則毋須貼上郵票)將填妥及簽署後的回執寄回，或親手交回本公司股份過戶處，香港中央證券登記有限公司，地址為香港灣仔皇后大道東 183 號合和中心 17M 樓。閣下同時亦可將申請(註明閣下的姓名、地址及要求)以電郵方式發送到 clover.ecom@computershare.com.hk 或以書面方式通知股份過戶處。請注意，(i)先前作出選擇收取公司通訊印刷本的指示將自收到股東指示當日起計一年內有效；(ii)若股東未於先前作出選擇，且此次未指定收取公司通訊印刷本，則將僅提供未來公司通訊的電子版本；及(iii)選擇收取所有未來公司通訊之印刷本，將自收到股東指示當日起計一年內有效，除非被撤銷或取代(以較早者為準)。因此，如果股東希望繼續接收未來公司通訊的印刷本，則需要再提出書面要求。

如閣下對本函件有任何疑問，請於辦公時間內(星期一至星期五(香港公眾假期除外)上午 9 時正至下午 6 時正(香港時間))致電股份過戶處熱線(852) 2862 8688 查詢。

承董事會命
三葉草生物製藥有限公司
董事長
梁朋博士

2025 年 5 月 21 日

附註 1：此函件致尚未提供電子郵件地址以接收可供採取行動的公司通訊之公司登記股東。若閣下為新登記股東，請閱讀以電子方式發佈公司通訊的安排，並按建議提供閣下的電子郵件地址。
附註 2：可供採取行動的公司通訊指任何涉及要求發行人的證券持有人指示其擬如何行使其有關證券持有人的權利或作出選擇的公司通訊。

* 僅供識別



當閣下寄回此回執時，請將郵寄標籤剪貼於信封上。
如在本港投寄，閣下無需支付郵費或貼上郵票。